These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25336728)

  • 1. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.
    Corbett KS; Katzelnick L; Tissera H; Amerasinghe A; de Silva AD; de Silva AM
    J Infect Dis; 2015 Feb; 211(4):590-9. PubMed ID: 25336728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.
    Montoya M; Gresh L; Mercado JC; Williams KL; Vargas MJ; Gutierrez G; Kuan G; Gordon A; Balmaseda A; Harris E
    PLoS Negl Trop Dis; 2013; 7(8):e2357. PubMed ID: 23951377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the human serum antibody response to secondary dengue virus infections.
    Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
    Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
    PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
    Katzelnick LC; Montoya M; Gresh L; Balmaseda A; Harris E
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):728-33. PubMed ID: 26729879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka.
    Tissera H; Amarasinghe A; De Silva AD; Kariyawasam P; Corbett KS; Katzelnick L; Tam C; Letson GW; Margolis HS; de Silva AM
    Am J Trop Med Hyg; 2014 Jul; 91(1):132-7. PubMed ID: 24865684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.
    Raut R; Corbett KS; Tennekoon RN; Premawansa S; Wijewickrama A; Premawansa G; Mieczkowski P; Rückert C; Ebel GD; De Silva AD; de Silva AM
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):227-232. PubMed ID: 30518559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.
    Clapham HE; Rodriguez-Barraquer I; Azman AS; Althouse BM; Salje H; Gibbons RV; Rothman AL; Jarman RG; Nisalak A; Thaisomboonsuk B; Kalayanarooj S; Nimmannitya S; Vaughn DW; Green S; Yoon IK; Cummings DA
    J Infect Dis; 2016 May; 213(9):1428-35. PubMed ID: 26704615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies.
    Buddhari D; Aldstadt J; Endy TP; Srikiatkhachorn A; Thaisomboonsuk B; Klungthong C; Nisalak A; Khuntirat B; Jarman RG; Fernandez S; Thomas SJ; Scott TW; Rothman AL; Yoon IK
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3230. PubMed ID: 25329173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
    Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
    J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue antibody in Thai children from maternally transferred antibody to acquired infection.
    Pengsaa K; Limkittikul K; Yoksan S; Wisetsing P; Sabchareon A
    Pediatr Infect Dis J; 2011 Oct; 30(10):897-900. PubMed ID: 21552182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003).
    Liebman KA; Stoddard ST; Morrison AC; Rocha C; Minnick S; Sihuincha M; Russell KL; Olson JG; Blair PJ; Watts DM; Kochel T; Scott TW
    PLoS Negl Trop Dis; 2012; 6(2):e1472. PubMed ID: 22363822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.
    Ito M; Katakai Y; Ono F; Akari H; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2011 Jun; 156(6):1073-7. PubMed ID: 21409446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
    de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
    BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human antibody response to dengue virus infection.
    Wahala WM; Silva AM
    Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.